-
Thematic Analysis
NewPsychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Dextromethorphan + Quinidine Sulfate) in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Dextromethorphan + Quinidine Sulfate) in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Dextromethorphan + Quinidine Sulfate) in Migraine Drug Details: Dextromethorphan hydrobromide...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Dextromethorphan + Quinidine Sulfate) in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Dextromethorphan + Quinidine Sulfate) in Treatment Resistant Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Dextromethorphan + Quinidine Sulfate) in Treatment Resistant Depression...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RVU-120 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RVU-120 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RVU-120 in Triple-Negative Breast Cancer (TNBC) Drug Details: RVU-120...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-1302 in T-Cell Acute Lymphocytic...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Drugs In Development, 2023’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Abicipar pegol in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abicipar pegol in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abicipar pegol in Diabetic Macular Edema Drug Details: Abicipar...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Deudextromethorphan Hydrobromide + Quinidine Sulfate) in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Deudextromethorphan Hydrobromide + Quinidine Sulfate) in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Deudextromethorphan Hydrobromide + Quinidine...
-
Company Profile
Avanir Pharmaceuticals Inc – Company Profile
Avanir Pharmaceuticals Inc (Avanir), a subsidiary of Otsuka Pharmaceutical Co Ltd. is a biopharmaceutical company that focuses on the research, development, and commercialization of medical and pharmaceutical treatments for central nervous system disorders. The company’s lead product include Nuedexta, a medication used for the treatment of pseudobulbar affect (PBA). The company's pipeline product include AVP-786 intended for the treatment of agitation in Alzheimer’s disease, residual schizophrenia, intermittent explosive disorder, disinhibition in dementia and traumatic brain injury behavioral dysfunction, among others....
Add to Basket